Napo科学顾问委员会 (SAB)成员、转移性乳腺癌患者Kelly Shanahan博士表示，管理救命癌症药物引起的副作用至关重要。据Jaguar总裁兼首席执行官Lisa Conte称，克罗菲尔默在为接受靶向治疗的乳腺癌患者提供持续性腹泻改善方面比安慰剂更有效。

In ONTARGET patients, glomerular filtration rate (GFR) decline averaged 0.9 ml/min per year, which is within the physiologic range of GFR loss (0.6–1.1 ml/min per year) observed in healthy ...

"As a cancer patient, having options to manage the side effects of life saving drugs is very important. I believe the published results of crofelemer for the prophylaxis of CTD are very exciting and ...

Jaguar Health (JAGX) announced that the U.S. Food and Drug Administration has granted Napo a Type C Meeting in the second quarter of 2025 to ...

The statistically significant responder analysis results for Mytesi ® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December ...